deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT05469100

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of LOXO-292

Sponsor: Eli Lilly and Company

Conditions Healthy Renal Insufficiency
Interventions Selpercatinib
Updated 4 times since 2022 Last updated: Aug 29, 2025 Started: Dec 19, 2018 Primary completion: Aug 7, 2019 Completion: Aug 7, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy and Renal Insufficiency, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 4 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2025 · 13 months · monthly snapshotCompleted~Oct 2025 – present · 11 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Oct 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

    First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • Loxo Oncology, Inc.
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations